P1393: BISPECIFIC CD19/CD37 CAR-T CELLS IN PATIENTS WITH REFRACTORY OR RELAPSED B-CELL LYMPHOMA

P1393: BISPECIFIC CD19/CD37 CAR-T CELLS IN PATIENTS WITH REFRACTORY OR RELAPSED B-CELL LYMPHOMA

Bibliographic Details
Main Authors:	Wenjing Luo, Chenggong LI, Yinqiang Zhang, Xindi Wang, Zhuolin Wu, Haiming Kou, Cong Lu, Danying Liao, Zejian Chen, Caiqin Chen, Lijun Wu, Wei Xiong, Jun Deng, Yu Hu, Heng Mei
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000972460.43253.39

Similar Items

Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies
by: Yinqiang Zhang, et al.
Published: (2023-04-01)

A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
by: Heng Mei, et al.
Published: (2021-10-01)

Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma
by: Chenggong Li, et al.
Published: (2023-01-01)

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
by: Hanren Dai, et al.
Published: (2020-04-01)

P1404: IL-10 PLUS THE EASIX SCORE PREDICT BLEEDING EVENTS AFTER ANTI-CD19 CAR T-CELL THERAPY
by: Xindi Wang, et al.
Published: (2023-08-01)

Successful treatment of relapsed acute B-cell lymphoblastic leukemia with CD20/CD22 bispecific chimeric antigen receptor T-cell therapy
by: Zuyu Liang, et al.
Published: (2020-12-01)

Development of a Bispecific Nanobody Targeting CD20 on B-Cell Lymphoma Cells and CD3 on T Cells
by: Yanlong Liu, et al.
Published: (2022-08-01)

A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
by: Ying Zhang, et al.
Published: (2021-05-01)

Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial
by: Ming Shi, et al.
Published: (2024-04-01)

Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial
by: Lixin Wang, et al.
Published: (2024-08-01)

Immunotherapy of B-Cell Lymphoma with an Engineered Bispecific Antibody Targeting CD19 and CD5
by: Frank Breitling, et al.
Published: (2013-05-01)

Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation
by: Hejin Jia, et al.
Published: (2019-06-01)

Timing of Tocilizumab Administration Under the Guidance of IL-6 in CAR-T Therapy for R/R Acute Lymphoblastic Leukemia
by: Yinqiang Zhang, et al.
Published: (2022-06-01)

Targeting autophagy overcomes cancer‐intrinsic resistance to CAR‐T immunotherapy in B‐cell malignancies
by: Lu Tang, et al.
Published: (2024-03-01)

Development of a Bispecific Antibody Targeting CD30 and CD137 on Hodgkin and Reed-Sternberg Cells
by: Sakthi Rajendran, et al.
Published: (2019-09-01)

Targeting CD22 for B-cell hematologic malignancies
by: Jia Xu, et al.
Published: (2023-10-01)

Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells
by: Alexandra Dreyzin, et al.
Published: (2023-03-01)

Antitumor activity of T cells secreting αCD133-αCD3 bispecific T-cell engager against cholangiocarcinoma.
by: Thanich Sangsuwannukul, et al.
Published: (2022-01-01)

Antitumor activity of T cells secreting αCD133-αCD3 bispecific T-cell engager against cholangiocarcinoma
by: Thanich Sangsuwannukul, et al.
Published: (2022-01-01)

Blocking the CD39/CD73 pathway synergizes with anti-CD20 bispecific antibody in nodal B-cell lymphoma
by: Carsten Müller-Tidow, et al.
Published: (2025-01-01)

The role of the tetraspanin CD37 in T and B cell responses
by: Wright, M, et al.
Published: (2005)

Binding domain on CD22 molecules contributing to the biological activity of T cell-engaging bispecific antibodies
by: Jie Chen, et al.
Published: (2023-07-01)

Plasma proteomic and metabolomic signatures of B‐ALL patients during CAR‐T cell therapy
by: Jianghua Wu, et al.
Published: (2023-03-01)

Selective lysis of acute myeloid leukemia cells by CD34/CD3 bispecific antibody through the activation of γδ T-cells
by: Faisal Al Agrafi, et al.
Published: (2024-12-01)

Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia
by: Justin C. Boucher, et al.
Published: (2023-12-01)

Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
by: Dina M Flink, et al.
Published: (2024-03-01)

Decitabine in combination with fludarabine and cyclophosphamide as a lymphodepletion regimen followed by CD19/CD22 bispecific targeted CAR T-cell therapy significantly improves survival in relapsed/refractory B-ALL patients
by: Yunju Ma, et al.
Published: (2023-04-01)

Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
by: Fumou Sun, et al.
Published: (2024-01-01)

Efficacy and safety of CD22-specific and CD19/CD22-bispecific CAR-T cell therapy in patients with hematologic malignancies: A systematic review and meta-analysis
by: Lili Li, et al.
Published: (2022-12-01)

CD20 expression regulates CD37 levels in B-cell lymphoma – implications for immunotherapies
by: Malgorzata Bobrowicz, et al.
Published: (2024-12-01)

First‐in‐human study of JNJ‐67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome
by: Rupa Narayan, et al.
Published: (2024-03-01)

A potent tetravalent T-cell–engaging bispecific antibody against CD33 in acute myeloid leukemia
by: Sayed Shahabuddin Hoseini, et al.
Published: (2018-06-01)

T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors
by: Jim Middelburg, et al.
Published: (2024-01-01)

The making of multivalent gamma delta TCR anti-CD3 bispecific T cell engagers
by: Eline van Diest, et al.
Published: (2023-01-01)

CRISPR screening identifies T cell-intrinsic regulators of CD3-bispecific antibody responses
by: Ryan D. Molony, et al.
Published: (2022-08-01)

Elimination of SHIV Infected Cells by Combinations of Bispecific HIVxCD3 DART® Molecules
by: Marina Tuyishime, et al.
Published: (2021-08-01)

Bispecific T cell engagers targeting CD20/CD3 in B-cell lymphoma: latest updates from 2023 EHA annual meeting
by: Shenhe Jin, et al.
Published: (2023-12-01)

CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
by: Regina Jitschin, et al.
Published: (2018-11-01)

Tetraspanins CD37 and CD151 differentially regulate Ag presentation and T-cell co-stimulation by DC.
by: Sheng, K, et al.
Published: (2009)

Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activity
by: Mary L. Faber, et al.
Published: (2023-08-01)